Oruka Therapeutics, Inc.
ORKA
Rank in Stocks
#3308
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Share Price
$80.01
Last synced: 2026-10-21
Market Cap
$5.30B
Change (1 day)
1.16%
Change (1 year)
200.21%
Country
US
Trade Oruka Therapeutics, Inc. (ORKA)
Category
Healthcare
Stock split history for Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. stock (symbol: ORKA) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 22, 2026.
One ORKA share bought prior to Oct 22, 2026 would equal to 0 ORKA shares today.
The most recent stock split occurred on Oct 22, 2026.
One ORKA share bought prior to Oct 22, 2026 would equal to 0 ORKA shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
